Eiger BioPharmaceuticals

For profitContributed to NMEWebsite ↗

Also known as: Eiger BioPharmaceuticals | Eiger BioPharmaceuticals, Inc | Eiger BioPharmaceuticals, Inc. | EIGER BIOPHARMS | Eiger Group International, Inc.

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 3

First clinical trial

Jul 1, 2009

First marketed drug

Nov 20, 2020

First NDA

Nov 20, 2020

Last known activity

Dec 15, 2021

Timeline

2000s

Jun 1, 2008
Eiger BioPharmaceuticals— Founded

2010s

Nov 18, 2015
Celladon Corporation— Acquired

2020s

Nov 20, 2020
lonafarnib— Marketing Organization
Nov 20, 2020
lonafarnib— NDA Organization
Nov 20, 2020
lonafarnib— NDA Secondary Org

Drugs by trial phase (16 distinct, 26 trials)

Phase 3 (8 own, 0 via acquisition)

Phase 2 (5 own, 2 via acquisition)

Phase 1 (1 own, 0 via acquisition)

ebp921

Indications

Studied for

Marketed drugs (1)

lonafarnib

Subsidiaries (1 direct, 1 total across the full acquisition tree)

Celladon Corporation

Recent trials (25)

NCT03895528Lead sponsorN/A—
NCT05070364Lead sponsorPhase 3Dec 15, 2021
NCT04652479CollaboratorPhase 2Jun 21, 2021
NCT05229991CollaboratorPhase 3May 15, 2021
NCT04727424CollaboratorPhase 3Jan 19, 2021
NCT04388709CollaboratorPhase 2May 31, 2020
NCT04343976CollaboratorPhase 2May 1, 2020
NCT04344600CollaboratorPhase 2Apr 30, 2020
NCT03719313Lead sponsorPhase 3Dec 1, 2018
NCT03373435Study directorPhase 2Mar 19, 2018
NCT03373435Lead sponsorPhase 2Mar 19, 2018
NCT02968641Lead sponsorPhase 2Mar 1, 2017
NCT03069508Lead sponsorPhase 2Feb 13, 2017
NCT02736149Lead sponsorPhase 2Dec 1, 2016
NCT02765802Study directorPhase 2Oct 19, 2016

Details

Founded: San Carlos, CA, US Jun 1, 2008
First NDA: Nov 20, 2020
Last known activity: Dec 15, 2021

Designations held

Orphan drug
Priority review
Breakthrough therapy